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Abstract
Camelpox virus (CMLV) is the closest known orthopoxvirus genetically related to variola virus. So far, CMLV was restricted to
camelids but, recently, three human cases of camelpox have been described in India, highlighting the need to pursue
research on its pathogenesis, which has been hampered by the lack of small animal models. Here, we confirm that NMRI
immunocompetent mice are resistant to intranasal (i.n.) CMLV infection. However, we demonstrate that CMLV induced a
severe disease following i.n. challenge of athymic nude mice, which was accompanied with a failure in gaining weight,
leading to euthanasia of the animals. On the other hand, intracutaneous (i.c.) infection resulted in disease development
without impacting the body weight evolution. CMLV replication in tissues and body fluids was confirmed in the two models.
We further analyzed innate immune and B cell responses induced in the spleen and draining lymph nodes after exposure to
CMLV. In both models, strong increases in CD11b
+F4/80
+ macrophages were seen in the spleen, while neutrophils, NK and B
cell responses varied between the routes of infection. In the lymph nodes, the magnitude of CD11c
+CD8a
+ lymphoid and
CD11c
+CD11b
+ myeloid dendritic cell responses increased in i.n. challenged animals. Analysis of cytokine profiles revealed
significant increases of interleukin (IL)-6 and IL-18 in the sera of infected animals, while those of other cytokines were similar
to uninfected controls. The efficacy of two antivirals (cidofovir or HPMPC, and its 2, 6-diaminopurine analog) was evaluated
in both models. HPMPC was the most effective molecule affording 100% protection from morbidity. It appeared that both
treatments did not affect immune cell responses or cytokine expression. In conclusion, we demonstrated that
immunodeficient mice are permissive for CMLV propagation. These results provide a basis for studying the pathogenesis
of CMLV, as well as for evaluating potential antiviral therapies in an immunodeficiency context.
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Introduction
Camelpox virus (CMLV) is a member of the genus Orthopoxvirus
(OPV) of the family Poxviridae [1,2]. In contrast to other OPV
members, such as vaccinia virus (VACV), cowpox virus (CPXV) or
monkeypox virus, CMLV remains poorly studied, although it is,
genetically, the closest virus related to variola virus (VARV) [2]. While
other OPVs can infect various hosts, including rodents, zoo animals,
monkeys and humans, VARV and CMLV are restricted to a single
host, humans for VARV and camels for CMLV, in which they induce
a severe disease. Old World (dromedary and Bactrian) camelids have
beenrecognized asthe reservoirhosts of CMLV, althoughNew World
camelids, such as guanacos, may be experimentally infected [3]. The
disease camelpox is endemic in almost every country in which camel
husbandry is practiced, and outbreaks have been reported in the
M i d d l eE a s t ,i nA s i a ,i nA f r i c aa n di ns o u t h e r np a r t so fR u s s i aa n d
India [4]. The transmission of camelpox is by direct contact or via
contaminated environment. Of note, arthropod vectors could also be
involved in the transmission of the disease [5].
Human cases of camelpox have been described as rare or
inexistent [6–8]. Indeed, few articles reported individuals with
lesions on the arms, or ulcers on the lips and in the mouth (from
drinking milk of infected animals), but they all remained
unconfirmed [6,8]. However, recently, camelpox has been
described as a possible zoonosis with three human cases identified
and laboratory confirmed in India [9]. These camel handlers, in
direct contact with camelpox-infected animals, developed skin
lesions localized on the fingers and the hands. Identification of
CMLV as the causative agent was made (i) based on the detection
of camelpox neutralizing antibodies in serum samples of the three
suspected cases, (ii) by amplification of a CMLV specific gene
(C18L), and (iii) by further amplification and sequencing of other
genes whose sequences were confirmed to match those of CMLV.
These findings should be taken into consideration in the actual
context of increasing number of OPV infections in humans and
animals. Indeed, the last years, outbreaks of CPXV infections have
been identified in European countries and involved humans, pets
(rats and dogs) and exotic zoo animals (elephants, mongooses,
jaguarundis) [10–14]. Also, zoonotic infections of buffalopox have
been reported in India [15], and VACV infections are seen in
humans, cattle and monkeys in Brazil [16,17]. It is hypothesized
that cessation of smallpox vaccination 30 years ago may have
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concept that is supported by the recent finding of a 20-fold
increase in human monkeypox incidence in Democratic Republic
of Congo [18]. However, camelpox appears largely restricted to
camels, and seldom produces clinical disease in humans. Reports
of human camelpox cases, either confirmed or not by virological
tests, have suggested a mild course of disease even though CMLV
is genetically more closely related to VARV than to other OPVs.
In camels, camelpox is a contagious proliferative skin disease
with localized or generalized vesicles on the skin and mucous
membranes of the lips and the nose [5,19,20]. The clinical
presentations observed are from mild to severe infections, which
may reflect the existence of strains of CMLV of variable
pathogenicity [8]. In agreement with previous reports, a recent
study showed that young calves and pregnant females were the
most susceptible to camelpox [4]. In the same study, the
morbidity, mortality and abortion rates were of 30–90%, 1–15%
and 80–90%, respectively [4]. Camelpox outbreaks cause not only
severe economic losses in camel breeding areas, as camels are used
for milk, meat, wool production, transport or racing [21], but also
require logistical measures of containment for avoiding the spread
in neighboring countries [22].
In this context, laboratories have conducted researches to
develop live attenuated (Dubai camelpox vaccine or Ducapox) and
inactivated camelpox vaccines [3,23,24]. For instance, a single
dose of Ducapox, given 6 years prior lethal challenge with CMLV,
could protect camels from camelpox disease and related death.
However, 6 to 9 month-old camels should receive a booster
injection for a full protection [3]. In addition to these prophylactic
options, post-exposure therapies could be of interest, particularly
in young camels, but they have not yet been investigated in vivo due
to the lack of small animal models. In vitro, ST-246 [TecovirimatH,
4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,
6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide] potently inhib-
ited CMLV replication in several cell culture models by preventing
the production of enveloped virus particles [25–27]. Also, several
inhibitors of viral DNA polymerase, such as the acyclic nucleoside
phosphonate HPMPC [cidofovir or VistideH, (S)-1-(3-hydroxy-2-
phosphoylmethoxypropyl)cytosine] and the 2,6-diaminopurine
analog HPMPDAP, have shown potent antiviral activities against
CMLV replication in vitro [28]. Also, ST-246, HPMPC and CMX-
001 (hexadecyloxypropyl-HPMPC) are currently recognized as
potent inhibitors of OPVs in vivo, as demonstrated in various animal
models [29,30]. ST-246 and CMX-001 are orally available and
HPMPC requires intravenous administration. These compounds
have been successfully used as emergency investigational new drugs
in humans for the treatment of life-threatening VACV infections
[31–37]. Based on these data, ST-246 and acyclic nucleoside
phosphonates could be considered as therapeutic options against
natural CMLV infections. However, their further evaluation
requires the availability of animal models.
For the past forty years, several studies have supported the
narrow host range of CMLV. Indeed, experimental inoculations of
CMLV into cattle, sheep, goats, rabbits, guinea pigs, rats, hamsters
and adult mice have been unsuccessful [22,38–41]. In one study,
monkeys challenged with CMLV strain Etha 78 developed typical
pox lesions passing all stages from day 8 to day 18 post-inoculation
[39], whereas in another report, monkeys inoculated with CMLV
strain CM-G2 did not develop a rash [38]. Suckling and two week-
old mice have been shown to be highly susceptible to certain
strains of CMLV given intraperitoneally or intracerebrally, with
50% lethal doses varying with the strain used [21,38,42]. Five day-
old or adult immunocompetent mice have been described resistant
to CMLV when inoculated intradermally, albeit such strains
caused considerable morbidity in camel herds or generalized pox
lesions and death of 10 month-old camels [22,40,43]. Neverthe-
less, the availability of small animal models of CMLV infection
would greatly enhance the understanding of CMLV pathogenesis,
including its immune evasion mechanisms, and would allow the
evaluation of (i) antivirals efficacy and (ii) the virulence of different
CMLV strains. Moreover, there are evidences that camelpox
might become a zoonosis, and severe forms of the disease should
be considered in immunocompromised individuals.
Thus, considering that common adult immunocompetent labora-
tory mice seemed being resistant to CMLV, we decided to focus on
immunodeficient mice. A similar approach has been successfully
reported with monkeypox virus [44,45]. Indeed, most of the
laboratory-derived immunocompetent mice appeared resistant to
monkeypox virus, while wild-derived inbred immunocompetent strains
(CAST/EiJ) and immunodeficient mice, such as SCID BALB/c,
C57BL/6 Stat1
-/- and 129 Stat1
-/-, were highly susceptible [44–46].
The aim of our work was to investigate whether four week-old
athymic nude mice might be permissive for CMLV replication and
propagation following intranasal (i.n.) or intracutaneous (i.c.)
challenge. We further evaluated if the delivery routes could exert
different pathogenic effects, as already reported for other OPVs
[Schriewer, J. et al., XVIII International Poxvirus, Asfivirus, and
Iridovirus Symposium, Sedona, Arizona, USA, June 5–10, 2010,
P8.12], [43], in terms of disease progression and outcome,
immune cell recruitment and cytokine production. Our findings
demonstrate that the survival and pathogenesis of nu/nu mice
depends on the route of infection which drives different patterns of
immune cell recruitment in the spleen and lymph nodes of infected
animals. In addition, the benefits of HPMPC and HPMPDAP
treatments given topically or systemically were assessed and it was
found that both treatments had an effect on CMLV-induced
disease with HPMPC offering 100% protection from morbidity.
Results
nu/nu mice are susceptible to i.n. and i.c. CML1 infection
In pilot studies, the pathogenicity of CMLV strain Iran (CML1)
was first evaluated in 4 to 5 week-old NMRI immunocompetent
mice, challenged via the i.n. route with 2.0610
6 PFU/mouse.
These mice were followed for 70 days after infection and did not
show any symptoms or loss of body weight (data not shown). This
is in line with published studies describing the lack of virulence of
CMLV in immunocompetent mice following intracranial or
intradermal inoculation [22,38]. Also, all of the animals
challenged with CMLV seroconverted with a 50% neutralizing
antibody titer mean of 1.5460.23 log10 at day 70 post-infection.
We then hypothesized that depletion of T cell-mediated responses
could facilitate camelpox disease. Indeed, it has been shown that
an effective cytotoxic T-lymphocyte response was important for
successful OPV clearance, for instance, by inducing interferon-c
(IFN-c)b yT H1 cytokines [47]. Athymic nude mice were chosen as
they lack thymic T cells, and animals at a young age (4 to 5 week-
old, corresponding to an average body weight of 13 to 15 g) were
used, since it was shown that susceptibility of mice to CMLV could
be age dependent [21]. Based on other animal models of OPV
infection, two routes of inoculation were investigated: i.n. and i.c.
by light scarification at the lumbosacral region [48]. Various
inocula were evaluated in both models to determine the conditions
required to reach 100% morbidity or mortality, and these results
are presented here. Of note, all animal’s deaths recorded in the
following experiments were induced by euthanasia based on
humane end-points in order to minimize pain and distress, as
defined in the materials and methods section.
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with CML1 at an inoculum of 2.0610
6 PFU/mouse failed to gain
weight at the same rate as uninfected mice, starting from day 10
post-infection (Figure 1A). This was accompanied with severe
disease progression, and clinical manifestations of camelpox were
seen and consisted of pox-like lesions along the tail and on the legs
(starting on day 25 post-infection) while the rest of the body
remained lesion-free. Edemas of the joints and of the tail could be
observed in some of the animals (Figure 2). For these reasons,
animals presenting both parameters, i.e. absence of body weight
take and severe disease, were euthanized and survival curves could
be established. As shown in Figure 1B, 100% of the i.n. infected
cohort was euthanized by day 45 post-infection. Virus replication
could be detected at days 25 and 45 post-infection in the sera and
the lungs of, respectively, 100% and 50% of the infected animals by
quantitative real-time PCR (qPCR, Figure 1C and D). CML1
DNA copies were also detected in liver and spleen at the same time
points (data not shown). Importantly, at earlier times, CMLV DNA
copies could not be detected in the sera and in various tissues
suggesting the spreading of the virus from the initial site of infection
(data not shown). The presence of CML1 in skin lesions was
confirmed by qPCR analyses of skin lesions (data not shown).
Interestingly, nu/nu mice infected with CML1 by scarification
(2.0610
6 PFU/mouse) exhibited a body weight evolution similar
to that of uninfected controls along the 75 days of the experiment
(Figure 1E). However, i.c. infected mice did develop ‘‘pock-like’’
primary lesions at the site of scarification, which further spread
towards the extremities. As shown in Figure 1F, animals were
scored for severity of lesions that appeared as soon as day 5 post-
infection and then extended to the tail and/or legs by day 30 post-
infection. In this model, the presence of CML1 was detected in the
serum of 50% of the mice, while all skin biopsies exhibited high
CML1 DNA copy numbers at days 30 and 45 post-infection
(Figure 1G and H). At similar time points, animals with CML1-
positive serum also demonstrated virus in the spleen and the tail,
indicating the systemic spread of the virus (data not shown). This is
further supported by the fact that, at earlier times, CMLV DNA
copies were only detected in skin biopsies and swabs, and not in
other tissues (data not shown).
These results demonstrated that i.n. infection with CML1
resulted in drastic failure in weight gain, which, associated with a
severe illness, led to death by euthanasia of the entire cohort. In
contrast, CML1 administrated by the i.c. route provoked primary
localized lesions, which then disseminated to the tail and/or legs of
the mice, but did not affect body weight as compared with
uninfected controls. We therefore wondered whether the differ-
ences in disease progression seen between the two models of
infection could be explained by the circulation of neutralizing
antibodies. Indeed, athymic nude mice can mount B cell
responses. Seroneutralization experiments were performed with
sera (n=4 mice per group) collected at days 25 and 45 post-
infection, and at days 30 and 75 post-infection for the i.n. and i.c.
infection, respectively. Animals challenged with CML1 via i.n. or
i.c. route did not produce neutralizing antibodies. Therefore,
CML1 delivery route is of importance in nu/nu mice to determine
the outcome of the disease.
Figure 1. CML1 is pathogenic for athymic nude mice. Body weight evolution (A, E), survival curve (B), viral titers (C, D, G, H) and disease
indices (F) recorded in nu/nu mice infected i.n. (A–D) or i.c. by light scarification on the back (E–H). (A–B, E–F) Ten mice per group (uninfected group
and CML1-infected group) were followed for 80 days for their body weight and disease progression. Survival curves (B) were built based on i.n.
infected animals that were euthanized due to (i) failure in gaining weight and (ii) severe disease when compared to uninfected controls (see materials
and methods section). Disease indices (F) were attributed as stated in materials and methods. (C–D, G–H) Viral loads (n=4 mice per time point) of
serum, liver or back skin samples of CML1-infected mice were determined by qPCR (see materials and methods) and plotted on a logarithmic scale as
viral DNA copies per 50 ml serum or per mg tissue. Results are presented as means6standard error of the mean (SEM). ***p,0.001: statistic
differences in body weight evolution (unpaired t test) and in survival (Log-rank test). Results are representative of three independent experiments.
doi:10.1371/journal.pone.0021561.g001
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To further study the two models, histopathology of various
tissue biopsies was undertaken. As depicted in Figure 3A, lungs,
at 45 days after i.n. instillation, lung tissue showed the presence of
dilated vessels in the interalveolar septa, but no inflammatory cells,
and alveolar macrophages were sparse. Also, the epithelium lining
the bronchioles was found normal, in comparison with lung tissue
of uninfected animals. In addition, the leg was swollen due to
massive edema of the muscular compartment; blood vessels
showed vasodilatation and the muscle fibers were dissected by a
mixed inflammatory infiltrate containing many macrophages; the
bone marrow was hypercellular due to hyperplasia of the white cell
series (Figure 3B, proximal leg). Histopathogical examination
of the tail showed a swelling due to a diffuse infiltrate of
neutrophils that extended from the deep dermis up to the
underlying bone; the inflammatory cells infiltrated in and between
the muscle fibers, and produced an irregular outline of the cortical
bone; increased numbers of osteoblasts and osteoclasts were seen
(Figure 3C, tail).
Figure 4A shows the back skin from mice infected by
scarification. At day 15 post-infection, foci of inflammation
around the deep part of follicles, comprised of eosinophils and
mononuclear cells, were seen. Fifteen days later, there were several
exophytic lesions, covered by hyperplastic squamous epithelium
that centrally invaginated to form a crater, filled with parakeratin
and inflammatory cells, as well as some exfoliated epithelial cells.
The hyperplastic epithelium contained few, scattered dyskeratotic
cells. The epithelium was focally eroded and replaced by a crusta.
At its base, the lesion was surrounded by a mixed inflammatory
infiltrate that extended into the underlying muscular layer. At day
45 post-infection, a partly exophytic, partly endophytic lesion,
comprising hyperplastic squamous epithelium that centrally
invaginated, was observed. In the stroma around this lesion, a
mononuclear inflammatory infiltrate was seen. Finally, at 72 days
post-infection (dpi), the skin presented a large erosion in which the
squamous epithelium was lost, and replaced by a crusta. In
addition, no hair follicles were left in the underlying tissue, and the
fatty tissue was broken up by thin collagenous strands containing
some mononuclear inflammatory cells.
As shown in Figure 4B, similar findings were observed in the
skin of the leg and of the tail at 45 dpi. The observations of the leg
at day 75 post-infection were comparable to those reported above
for the i.n. model. However, in some areas, neutrophils
predominated and formed small abcess-like accumulations in
which nuclear dust was found. The inflammatory infiltrate
encroached focally upon the cortical bone resulting in piecemeal
break-down and irregular outline. The tail showed focal epithelial
hyperplasia and ulceration, covered by a crusta containing
parakeratin; in the epithelium, scattered dyskeratotic cells were
seen. At the base of this lesion, a band-like mononuclear
inflammatory infiltrate was observed (Figure 4B).
CML1 infection affects innate and B cell responses
The route of CML1 administration appeared to drive the
disease outcome. In this context, we speculated that immune
responses induced in each model could help understanding CML1
pathogenesis. Athymic nude mice lack thymic T cells, but have
potent innate immune, as well as B cell, responses. We determined
the changes in the number of macrophages, neutrophils, NK cells
and B cells in the spleen and in a pool of draining lymph nodes
(DLNs; axillary, inguinal, mesenteric and lumbar) after exposure
to CML1, in comparison with non infected animals, by flow
cytometric analysis at days 25 and 45 post-infection for the i.n.
model, and at days 30 and 75 post-infection for the i.c. model. Of
note, we observed a severe enlargement of the lumbar lymph
nodes in both models, and scarified-animals also exhibited
moderate enlargement of inguinal and axillary lymph nodes, as
seen at days 30 and 75 post-infection.
Analysis of splenocytes revealed a significant and sustained
recruitment of CD11b
+F4/80
+ macrophages and a strong, but
transient, increase of CD11b
+Gr1
+ neutrophils in the spleen after
i.n. CML1 inoculation (Figure 5A and B). A comparable pattern
of macrophage increase was seen after i.c. infection, whereas the
neutrophil population only rose at 75 dpi (Figure 5E and F). In
Figure 2. Symptoms observed at day 30 post-infection in nu/nu mice infected i.n. with CML1. Note the vesicles localized on the leg (A
and B), the swelling of the joint of the leg (B and C), and the presence of lesions along the tail (D and E). Similar symptoms are seen with i.c.
infection.
doi:10.1371/journal.pone.0021561.g002
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eosin-stained tissues are shown at day 45 post-infection for uninfected nu/nu mice (upper panels) and animals infected with CML1 by i.n. instillation
(lower panels). (A) In CML1 infected animals, in comparison with uninfected animals, the lung tissue is characterized by open alveolar spaces,
bronchioli without changes, and some dilated vessels in the interalveolar septa. (B) The disease induced in CML1 infected animals is also
characterized by a massive edema of the muscular compartment of the proximal leg. (C) Histopathological changes in the tail upon infection are
indentified by a diffuse infiltrate of neutrophils that extends from the deep dermis up to the underlying bone. Magnifications are indicated on each
panel, and the 106or 206images represent the boxed region of the corresponding 2.56image.
doi:10.1371/journal.pone.0021561.g003
Figure 4. Histology of back skin (scarified-zone), proximal leg and tail in nu/nu infected by scarification with CML1. (A) Hematoxylin
and eosin-stained skin tissues are shown for uninfected and CML1-scarified nu/nu mice at 15, 30, 45 and 75 dpi. Inflammation is centered around hair
follicles, as well as in the deep muscle, and the hyperplastic epithelium invaginates to form a crater. (B) Histological examinations of proximal leg and
tail of CML1-scarified nu/nu mice are shown at 45 and 75 days after virus infection. Note the epithelial hyperplasia and ulceration in the skin of the leg
and of the tail, and the massive edema that extends between individual muscle fibers of the leg at 75 dpi. Magnifications are indicated on each panel,
and the 106images represent the boxed region of the corresponding 2.56image.
doi:10.1371/journal.pone.0021561.g004
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DX5
+ subset was observed at 25 dpi following i.n. challenge. In
contrast, no significant changes in NK cell populations were
noticed after i.c. inoculation (Figure 5C and G). After i.n.
infection, B220
+CD19
+ B cell subset was slightly decreased at days
25 and 45 post-infection, and this trend was also viewed in the i.c.
model (Figure 5D and H). It has to be mentioned that the
decreased trend of the B220
+CD19
+ population was not
statistically significant in other independent experiments. Our
results suggest that the recruitment of neutrophils, DX5
+ NK cells
and B220
+CD19
+ cell population differ to some extent between
the two models, while macrophages are similarly recruited.
Analysis of the DLNs i.n. and i.c. inoculations revealed no
changes in the levels of DX5
+CD3
- NK cells and of B220
+CD19
+
mature B cells in both models, compared with the uninfected
controls (data not shown). In contrast, after i.n. challenge, the
amounts of CD11c
+CD8a
+ lymphoid and CD11c
+CD11b
+
myeloid dendritic cells (DCs) appeared increased at 25 dpi, in
comparison with uninfected nu/nu mice (Figure 6A and B).
However, these differences were not statistically significant but
were seen in two independent experiments. At 45 dpi, the levels of
the two DC subsets were comparable to those of the controls. In
contrast, at 30 dpi, there was a little trend of decreased amounts of
lymphoid and myeloid DCs in DLNs of mice inoculated by the i.c.
route compared with the controls, while at 75 dpi, both DC
populations remained constant (Figure 6C and D). Therefore,
both routes of inoculation only induced small changes in the
distribution of the various cell populations (i.e., DCs, NK and B
cells) found in the DLNs.
CML1 infection alters cytokine profiles in the sera
A number of cytokines have been shown to play important roles
in the virulence or in the resolution of acute infection of OPVs
[49–51]. Thus, to better understand the contrast seen between the
i.n. and i.c. route of infection, we aimed to examine cytokine
responses in the serum of animals exposed to CML1. For that
purpose, sera were collected on days 25 and 45, and on days 30
and 75 after virus exposure for the i.n. and i.c. model, respectively.
Four animals per group and per time point were used. As shown in
Figure 7A, i.n. CML1 challenge resulted in significant increase of
interleukin (IL)-18 at day 45 post-infection as compared with
uninfected controls; though this trend was already seen at 25 dpi.
A 4-fold increase in the levels of IL-6 was recorded upon i.n.
infection, albeit only low levels of IL-6 were detected (mean levels
of 20 pg/ml), compared with uninfected controls. This increase
has been further confirmed in an additional ELISA assay (see
materials and methods) which showed mean IL-6 levels of
71634 pg/ml and of 65623 pg/ml in the sera of i.n. infected
mice at, respectively, 25 and 45 dpi, while the uninfected animals
had IL-6 levels under the limit of detection. IL-1b appeared very
slightly up-regulated after CML1 exposure, but precaution should
be taken to interpret this result as the significance is based on a p
value of 0.0456. All the other cytokines evaluated in the i.n. model
had levels similar to those of the uninfected animals.
Interestingly, a similar cytokine profile was seen in the i.c. model
with IL-18 levels being boosted in response to CML1 scarification,
while the levels of the other cytokines were in the range of the
controls, including IL-6 (Figure 7B). This result, further
confirmed with an ELISA assay, highlighted the discrepancies in
IL-6 levels seen between the two models, although precaution
should be taken as the IL-6 levels observed in the i.n. model were
low.
Systemic HPMPC, and to a lesser extent HPMPDAP,
protect nu/nu mice against severe disease development
after i.n. challenge with CML1
To investigate the feasibility of using the i.n. model for the
evaluation of antivirals, we assessed the efficacy of HPMPC and of
HPMPDAP. The choice of HPMPDAP was based on its 10-fold
higher antiviral activity against CML1 in cell culture, compared to
HPMPC [28]. Four-week old mice were infected i.n. with
2.0610
6 PFU of CML1, and treated intraperitoneally for 3 days,
once per day, with 50 mg/kg of HPMPC and HPMPDAP or with
PBS (placebo). As shown in Figures 8A and 8B, body weight
curve of animals infected with CML1 and non-treated significantly
diverged from that of the uninfected group from day 17 post-
Figure 5. Identification of changes in immune cell populations from spleen of nu/nu mice exposed to CML1. Mice (n=4 per group)
were challenged i.n. (A–D) or i.c. (E–H) with PBS (uninfected) or with CML1 at a dose of 2.0610
6 PFU. At 25 and 45 dpi for the i.n. model or at 30 and
75 dpi for the i.c. model, spleen were harvested and CD11b
+F4/80
+ macrophages, CD11b
+Gr1
+ neutrophils, DX5
+ NK cells and B220
+CD19
+ mature B
cells were identified by FACS. Results are presented as percent gated cells. Bars represent mean6SD, standard deviation (n=4). ***p,0.001; **p,0.01
and *p,0.05: CML1 differs significantly from uninfected group as determined by unpaired t test; representative of two independent experiments.
doi:10.1371/journal.pone.0021561.g005
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and 45 post-infection based on our defined end-points (see
materials and methods). In contrast, HPMPC treatment protected
mice from changes in body weight and severe illness (Figures 8A
and 8B). Animals infected and treated with HPMPDAP showed
significant failure in weight gain, compared to uninfected group,
which started at day 5 post-infection, and 40% of these mice did
develop severe disease requiring euthanasia (Figure 8A). From
the entire HPMPDAP cohort, 60% of the animals survived CML1
challenge, as seen at day 70 post-infection (Figure 8B).
As depicted in Figure 8C and D, virus dissemination was
confirmed in the serum, liver, lungs, spleen and lymph nodes of all
animals of the CML1 group, and the viral DNA loads showed that
animals were similarly infected. The presence of viral genome in
skin lesions of the tail or leg was also validated. Under HPMPC
treatment, CML1 viral genome remained undetected in the
serum, lungs, spleen and lymph nodes at days 25 and 45 post-
infection. However, at 25 dpi, one mouse did show virus DNA
copies in the liver, and two mice had positive swabs of the tail and
of the leg, but these viral DNA loads were still significantly lower
than those seen in the CML1 group. At day 25 post-infection,
HPMPDAP treatment significantly reduced viral DNA loads in
the serum, liver, spleen and swabs compared to those of CML1-
group. Also, at that day, the only organs that remained free of
CML1 under HPMPDAP therapy were the lymph nodes. At 45
dpi, depending on the organ analyzed, one to three out of four of
the euthanized mice exhibited CML1 DNA copies. This suggests
that systemic administration of HPMPDAP for 3 days was not as
effective as HPMPC for preventing CML1 dissemination in nu/nu
mice.
Topical HPMPC and HPMPDAP affect CML1
dissemination in nu/nu mice following i.c. infection
We further wanted to determine whether the scarification model
could be useful for evaluating the antiviral efficacy of cream-based
therapeutics. The efficacy of 1% HPMPC-cream has already been
shown against cutaneous VACV or CPXV infections in immuno-
deficient mice [52,53]. Here, in addition to an HPMPC-cream, we
also evaluated the antiviral activity of an HPMPDAP-cream against
CML1-induced disease. Athymic nude mice were inoculated with
CML1 by light scarification at the lumbosacral region. Topical
treatments of 1% HPMPC- or HPMPDAP-cream were given once
daily for 5 days, starting the day of infection, and mice were
followed for 75 days after virus contact. As expected, no changes in
bodyweight wereseen betweenthedifferent groups (Figure9A). In
addition, HPMPC and HPMPDAP therapies abolished lesion
development at the site of scarification and propagation to the tail
and/or leg through the 75 days of monitoring, as demonstrated in
Figures 9B and C. It has to be noticed that the 1%-HPMPC
formulation could cause skin irritation, which was not observed in
the placebo- or HPMPDAP-group (data not shown).
Viral loads in various samples were then determined at days 30 and
75 post-infection. For that purpose, four mice of each group were
chosen at random, sacrificed at both time points and their scores
(disease indices) were recorded. As shown in Figure 9D, all animals
from the CML1-cohort had mean scores of 4 and 5, demonstrating
the severity of the lesions.It has to be mentioned that the backlesion of
one mouse killed at day 75 post-infection was almost healed but this
animal still had severe lesions on the tail and swollen joints. The
HPMPC-group had no signs of disease (score of zero). Interestingly, a
Figure 6. DLN responses to CML1 in nu/nu mice following i.n. or i.c. infection. Mice received PBS (uninfected) or 2.0610
6 PFU of CML1. At
25 and 45 dpi for the i.n. model (A–B) or at 30 and 75 dpi for the i.c. model (C–D), DLNs (pool of inguinal, axillary, mesenteric and lumbar lymph
nodes) were collected and the CD11c
+CD8a
+ lymphoid and CD11c
+CD11b
+ myeloid DCs were identified. The magnitude of DC responses is depicted
as percent gated cells plotted on box- and whiskers-graphs. Bars represent Min to Max whiskers (n=4 individual mice for each group). Results were
submitted to unpaired t test but the differences between the groups were not significant.
doi:10.1371/journal.pone.0021561.g006
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30 post-infection, while the others remained disease free. As shown in
Figure 9D, animals belonging to the CML1-cohort exhibited
intermediate to high viral loads among the various samples. Per time
points and per samples, CML1 copy numbers were nicely grouped to
each other, with the exception of spleen and serum samples at day 30
post-infection. At 30 dpi, viral loads found in skin biopsies were
diminished approximately by 10,000-fold after HPMPC treatment,
compared with the CML1-group, which showed an average viral
DNA copies of 5610
6 (Figure 9D). HPMPC treatment resulted in
undetectable levels of CML1 at 30 dpi in swabs from skin and tail, and
in sera, spleen and lymph nodes, compared to those of the CML1-
Figure 7. Cytokine production in the sera of nu/nu after exposure to CML1. Sera from mice inoculated i.n. (A) or i.c. (B), isolated at two time
points after exposure to PBS or to CML1, were used to measure cytokine levels by ELISA. Data are the average6SEM (n=4 mice for each group).
***p,0.001; **p,0.01 and *p,0.05, CML1 versus the corresponding values of the uninfected group by unpaired t test. Boxed regions represent a
zoom-in of the corresponding field, i.e., IL-1b and IL-6.
doi:10.1371/journal.pone.0021561.g007
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was still seen with a strong reduction or inhibition of viral loads in the
skin biopsies, skin and tail swabs and serum. However, HPMPC only
delayed viral dissemination to the spleen and the lymph nodes at day
75 post-infection, since, respectively, 50% and 75% of the animals had
viral loads similar to those of the CML1-group.
HPMPDAP topical treatment afforded strong reductions in viral
DNA loads in the various samples recovered in 3 out of 4 animals at
day 30 post-infection. At this time point, the mouse that showed high
viral DNA copies, not only in the skin biopsy, but also in most of the
other samples examined (i.e., skin swab, serum and lymph nodes),
corresponded to the one reported with a disease index of 1
(Figure 9D). At 75 dpi, statistically significant diminutions in viral
DNA loads, reaching sometimes undetectable levels, were seen in the
skin biopsies, swabs and sera recovered from mice under HPMPAP
therapy. Similarly to HPMPC, topical HPMPDAP provided only
partial effect in reducing titers in the spleen and lymph nodes. As a
general conclusion, both topical treatments inhibited the develop-
mentofprimarycutaneouslesionsand ofsatellitelesionsaswell,at30
and 75 dpi, but failed to clear the entire cohorts at later time points
from CML1 spread to the spleen and the lymph nodes.
Immune responses and cytokine production following
HPMPC and HPMPDAP treatments are similar to those of
the uninfected animals
Finally, in order to explore whether HPMPC or HPMPDAP
treatments could have an effect on the immune system to help for
Figure 8. HPMPC protects against lethal CML1 i.n. challenge, whereas HPMPDAP showed an intermediate protection. Nu/nu mice
were inoculated i.n. with PBS (uninfected group) or with CML1 at a dose of 2.0610
6 PFU (CML1, HPMPC and HPMPDAP groups). HPMPC and
HPMPDAP groups were treated intraperitoneally for 3 days, starting the day of infection, with 50 mg/kg of HPMPC or HPMPDAP, respectively;
uninfected and CML1 groups received a similar treatment regimen but with PBS. Animals were monitored for 70 days for body weight (A). Survival
curves (B) were built based on i.n. infected animals treated or not that were euthanized due to (i) failure in gaining weight and (ii) severe illness in
comparison with uninfected controls (see materials and methods). Viral loads in the serum and various organs (C) and in skin swabs of tail and leg (D)
were determined by qPCR at days 25 and 45 post-infection. Data are mean6SEM. Statistical analyses were performed as described in materials and
methods. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0021561.g008
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spleen and DLNs (by FACS analysis) and compared cytokine
induction in sera (by ELISA) among the different cohorts. During
the animal experiments in which the antiviral activities of HPMPC
and HPMPDAP were assessed, samples were collected and used
for these analyses. FACS experiments performed on spleen and
DLNs revealed that the levels of immune cells, such as
macrophages, neutrophils, NK, B, lymphoid and myeloid DC
cells, in the infected-treated cohorts were comparable with those of
uninfected animals. Likewise, levels of cytokines were comparable
between infected-treated animals and uninfected mice. Thus, at
the time-points investigated, the treated animals exhibited immune
and cytokine responses that were similar to those of naı ¨ve animals.
Discussion
In this report we described the establishment and the
characterization of two immunodeficient mouse models of CMLV
infection. The choice of an immunodeficient model was based on
the literature [38,41] and on our data confirming that four to five
week-old immunocompetent mice were resistant to i.n. CMLV
infection and that the entire cohort had neutralizing antibody
titers against CMLV. This avirulent phenotype could be
circumvented by using severe combined immunodeficient (SCID)
mice, which lack B and T cells (data not shown), and athymic nude
mice, which lack a normal thymus and thus functionally mature T
cells. We observed that i.n. or intraperitoneal administration of
CMLV to SCID mice induced 80% mortality between 20 to 30
dpi at a dose of 3610
5 and 4610
6 PFU, respectively (data not
shown). Further experiments performed in athymic mice showed
that CMLV given i.n., i.c. or intraperitoneally rendered animals
sick. Disease appearance and CMLV-related death (by euthanasia)
in nu/nu mice were observed later to what was seen with the SCID
mice. Therefore, the involvement of B cell responses might be then
hypothesized for slowing down camelpox disease progression. We
focused our works on nu/nu mice, which are partially immuno-
suppressed, and decided to investigate the two routes of infection
that resemble those occurring in the natural host.
We showed that CMLV given by the i.n. and the i.c. route
induced the development of camelpox disease in nu/nu mice. In
both models, the clinical signs of camelpox disease were noticeable
with appearance of lesions along the tail, starting from its base
towards the extremity, together with edemas of the tail and/or of
the joints of the feet and legs. The outcome was different
depending on the model of infection, one altering the body weight
evolution and leading to death by euthanasia while the other
model not. The progression and severity of camelpox disease was
measured (i) in the i.n. model by the absence of body weight gain
associated with severe illness which justified the euthanasia of the
animals and (ii) in the i.c. model by the development of cutaneous
ulcerations. Also, monitoring of the disease was possible by
performing qPCR on various tissues, body fluids and swabs.
Consequently, the two models offered suitable features for
enabling the visual and molecular evaluation of antiviral drug
efficacies.
In general, the disease observed upon CMLV infection in nu/nu
mice was prolonged, in contrast with what is seen with pathogenic
OPVs such as VACV strain Western Reserve (VACV-WR).
Indeed, at doses of virus ranging from 10
4 to 10
6 PFU, i.n.
infection with VACV-WR resulted in death of all nu/nu mice by
day 9 post-infection [54], while mortality by euthanasia was
observed between days 32 to 45 post-infection with CMLV (dose
of 2610
6 PFU). This difference in pathogenicity can also be seen
in the i.c. model in which CPXV strain Brighton (CPXV-Br) or
VACV-WR inoculated to nu/nu mice at a dose of 10
4 PFU
induced death of the entire cohort at day 12 after virus exposure
(our unpublished data), while animals scarified with CMLV (dose
of 10
4 PFU) did not exhibit signs of disease. However, increasing
the dose of CMLV in the i.c. model caused development of lesions
at the site of scarification and their propagation to the tail and/or
legs. Therefore, in comparison with other pathogenic OPVs,
CMLV exhibits an intermediate phenotype with an attenuated
degree of virulence in mice. However, CMLV virulence appears to
be similar to that seen with vaccine strains of VACV, such as
Lederle and Lister, in immunodeficient mice. Indeed, VACV
strain Lederle administrated i.n. to nu/nu mice at a dose of
2610
6 PFU led to death of the animals between days 23 to 33
post-infection, while a 100-fold lower virus dose induced 25%
mortality (our unpublished data). Furthermore, i.c. inoculation of
VACV strain Lister (dose of 5610
5 PFU) to athymic nude mice
resulted in death at day 3467 post-infection [55].
In terms of histopathology, examination of cutaneous lesions
described in the i.c. model revealed epithelial hyperplasia,
inflammation centered on the hair follicles that extended into
the deep muscle in some cases, and development of tumor-like
lesions. These features could resemble the histological descriptions
of skin lesions found not only in animals infected i.c. with other
OPVs such as ectromelia virus (ECTV) [48], but also in humans
with VARV, monkeypox virus and molluscum contagiosum virus
[56–58]. In the case of the i.n. model, lung histology demonstrated
the presence of dilated vessels in the interalveolar septa without
signs of inflammation. More pronounced respiratory infections of
mice have been described following i.n. route with ECTV, VACV
and CPXV which provoked lung inflammation, necrotizing
bronchopneumonia and bronchiolitis, respectively [48]. However,
our observations are comparable to those showing that lethal i.n.
CPXV infection performed with a volume of virus of 5 ml led to
absence of histological changes of the lungs, while a volume of
50 ml resulted in pneumonitis [50]. We hypothesized that the 10 ml
volume used for CMLV infection might have confined patholog-
ical changes to the upper respiratory tract.
From our experiments, it appeared that (i) T cell responses were
essential for controlling CMLV infection in immunocompetent
animals, which is in agreement with published data on other
OPVs [59–61], (ii) the site of virus entry might give different
immune responses which could be responsible for different disease
outcome, and (iii) eventually, the genetic background of CMLV
itself may help understanding its attenuated virulence phenotype,
such as the absence or presence of specific immunomodulatory
Figure 9. Effects of topical HPMPC and HPMPDAP against CML1 propagation in cutaneously infected nu/nu mice. Animals were
scarified with PBS (uninfected group) or with CML1 at a dose of 2.0610
6 PFU (CML1, HPMPC and HPMPDAP groups). Topical application of 1%
HPMPC- and HPMPDAP-cream started the day of infection for 5 days, once per day. Uninfected and CML1 groups were treated similarly with a
placebo-cream. Animals were monitored for 75 days for body weight (A, n=5), lesions development (B–C), and viral loads (D). B; Disease indices or
scores were given as stated in materials and methods. Data are mean6SEM (n=5). C; photos were taken at 4, 18, 30, 46 and 75 dpi, and show the
evolution of the primary lesions and their spread to the tail. D; the disease index of the sacrificed mice (n=4 per group) is shown. Viral loads in
various tissues and swabs were determined by qPCR at days 30 and 75 post-infection. Data are mean6SEM. For statistical analyses, see materials and
methods. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0021561.g009
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findings with CMLV might help to understand some of the
mechanisms used by VARV to evade the host immune system
since both viruses share common biological properties including
their closely related genomic sequences, their single host species
and their poor pathogenicity in adult immunocompetent mice
[38].
As a first step to understand the differences seen in the
pathogenicity induced by CMLV when it was given i.n. or i.c., we
characterized the immune responses induced by CMLV challenge,
and the cytokines produced in sera as well. It has indeed been
shown that following i.n. or intradermal VACV-WR infection in
BALB/c mice, marked differences were seen in the pathogenesis
and in the cellular inflammatory response [62]. O’Gorman and
colleagues have recently evidenced that VACV immunization
induced a TLR2- and IL-6-dependent STAT3 pathway, while
lethal ECTV infection did not activate STAT3 [63]; albeit this was
observed using two different viruses. Finally, Abadie et al. have
nicely shown that modified VACV Ankara (MVA) administrated
via the intradermal or intramuscular route could recruit antigen-
presenting cells (APCs) in a different manner, priming different T
cell responses and thus shaping different quality of cytokine-
producing virus-specific T cells [64]. Therefore, the route of OPV
infection, including CMLV, can result in different pathogenicity
by inducing distinct immune responses [Schriewer, J. et al., XVIII
International Poxvirus, Asfivirus, and Iridovirus Symposium,
Sedona, Arizona, USA, June 5–10, 2010, P8.12] [43,65].
Nude mice, even though lacking functional T cells, can mount
innate immune and B cell responses. At day 25 post-infection, i.n.
infection resulted in substantial flow of macrophages, neutrophils
and DX5
+ NK cells in the spleen, while the pool of B cells
decreased. Moreover, at the same time, recruitment of myeloid
and lymphoid DCs was noticed in the DLNs. Intracutaneous
infection, in contrast, resulted in an influx of macrophages in the
spleen at days 30 and 75 post-infection, while slight accumulation
of neutrophils was observed only at late time point, and no change,
compared to uninfected controls, was found in the DLNs. In
conclusion, the two models recruited or diminished different cell
population pools in response to CMLV, even though they
exhibited comparable massive macrophage invasion. In both
models, the presence of neutralizing antibodies was not detected.
We further examined the cytokines released in the sera of nu/nu
mice after i.n. or i.c. challenge. Poxviruses possess various immune
evasion strategies to counteract host cell-mediated immunity. To
this end, CMLV expresses for example proteins that bind IFN-c,
IFN-a/b, CC chemokines, tumor necrosis factor and IL-1b [2].
Cytokines such as IL-2, -4, -5, -10, -13, -17 and IFN-c, tumor
necrosis factor (TNF)- a, macrophage and granulocyte-macro-
phage colony stimulating factor (M-CSF and GM-CSF, respec-
tively) in infected animals were in the same range as in uninfected
controls. In our hands, i.n. inoculation provoked a very slight
increase in IL-1b level at 45 dpi. However, IL-1b may be inactive
since CMLV possesses two ways for inhibiting IL-1b activity. The
first way could be the production of a viral soluble receptor for IL-
1b, encoded by three CMLV genes CMLV193, 194 and 196 which
are multiple regions of the VACV B16R IL-1 binding protein;
although there are no proofs that these small open reading frames
are functional [1]. The second way is the production of a caspase 1
inhibitor, known as SPI-2 (CMLV191 gene homolog to VACV
B13R gene [1]), which blocks the cleavage of proIL-1b into IL-1b
[1].
Intranasal CMLV inoculation of immunocompromised mice
led to significant increases of IL-6 levels by approximately 4-fold.
Nevertheless, this increase remains much lower than that observed
in immunocompetent mice upon lethal VACV or CPXV infection
for which, in comparison with uninfected controls, a 60-fold
increase in IL-6 concentrations has been recorded [50,66]. It is
recognized that IL-6 deficient animals are highly susceptible to
OPV infection demonstrating its role for surviving an OPV
infection [49,63]. However, as hypothesized by Smee et al., the
hyper-induction of IL-6 and its sustained levels might be
deleterious for the host, counteracting the beneficial role of timely
release cytokines for helping virus clearance [50].
Both routes of CMLV inoculation induced an increase in IL-18
levels. These findings may reflect our FACS data since this pro-
inflammatory cytokine can be produced by macrophages.
Interestingly, although the IL-18 increase was measured after
CMLV contact, IFN-c levels in CMLV-infected animals were
similar to those of uninfected animals. In contrast to VACV,
VARV or ECTV, CMLV does not encode for an IL-18 binding
protein, although IL-18 is a key pro-inflammatory cytokine,
originally identified as an IFN-c-inducing factor. IL-18 has been
shown to induce Th1 responses, NK cell activation and T cell
proliferation, and to induce host-derived IFN-c [67]. OPV IL-18
binding proteins have been shown to promote virulence by
decreasing IFN-c levels, and NK and T cell activities as well [68].
The authors have also described that IL-18 was still produced after
in vivo VACV infection, demonstrating that IL-18 binding protein
did not affect levels of IL-18 in the lungs. According to these
findings and our data showing the recruitment of DX5
+ NK cells
in the spleen and increased IL-18 levels, we expected to see
elevated levels of IFN-c in the sera (although we might have failed
to detect it because our first time point was 25 dpi). In addition,
Alcami et al. described that the soluble receptor of IFN-c produced
by CMLV could, in vitro, bind and inhibit the biological activity of
human, bovine and rat IFN-c, but not mouse IFN-c, favoring the
hypothesis that IFN-c could have been induced in response to
CMLV [69]. We can also speculate that the absence of IFN-c
production could be explained by the activity of the CMLV097
gene product. The CMLV097 gene is homolog of the VACV H1L
gene that encodes for a dual-specificity protein tyrosine phospha-
tase, which has been shown to dephosphorylate STAT1 and thus
prevent the induction of IFN-c [70].
From these data, it appears that the differences in outcome
upon i.n. and i.c. challenge do not seem being related to difference
in cytokine profiles. However, in this study, FACS and cytokine
analyses were performed late after virus exposure. In further
experiments, earlier, as well as closer time points should be
considered in order to evaluate whether striking discrepancies
between the two models exist and to investigate whether a
transient induction of IFN-c may occur. Moreover, early immune
responses should be studied not only in nu/nu mice, but also in
CMLV-resistant immunocompetent mice, with the aim to identify
the immune events trigger by these two types of infection.
To our knowledge, this is the first time that the benefit of an
antiviral therapy has been evaluated in vivo against CMLV. Two
compounds among the acyclic nucleoside phosphonate family
were tested, but HPMPC was used as a proof of concept for
validating our in vivo models to assess therapeutics. Indeed,
HPMPC has already proved its anti-poxvirus activity in vivo for
several years now and is widely used as reference compound in
animal studies involving poxviruses [71]. In our hands, systemic
HPMPC (50 mg/kg for 3 days once a day) protected nu/nu mice in
the i.n. model from camelpox disease and related death by
euthanasia. Furthermore, following HPMPC treatment, CMLV
was cleared from the serum, liver, spleen, lungs and lymph nodes,
and no signs of sickness were seen at the end of the experiment. In
contrast, although promising from the in vitro studies, HPMPDAP
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molecule HPMPC, since HPMPDAP protected 60% of the
animals from death by euthanasia, and 25% to 50% from
systemic spread of the virus, as shown by viral DNA loads. In
addition, signs of toxicity were seen following systemic HPMPDAP
treatment in nu/nu mice aged of four to five weeks, while this was
not reported in adult NMRI mice [72]. Regarding the i.c. model,
topical treatment with 1% HPMPC abolished primary cutaneous
lesions and inhibited the development of lesions on the tail and/or
legs, as well as the edemas of the joints. In agreement with that,
viral loads in skin biopsies were reduced by 10,000-fold and
circulating CMLV was not detected in the sera, spleens and lymph
nodes at day 30 after virus exposure. At the end of the experiment,
no recurrent lesions were visualized in the treated group, although
a systemic presence of CMLV was found in most of the animals.
These results demonstrated that HPMPC-cream slowed camelpox
disease progression and was not able to counteract the systemic
dissemination of CMLV. Smee and colleagues reported compa-
rable observations with VACV, although their model in
cyclophosphamide immunosuppressed mice was lethal [53]. The
protection afforded by a 1%-HPMPC-cream against VACV-WR
reduced the severity and the spread of the lesions, and delayed
death. Additionally, topical administration of 1% HPMPC-
DMSO solution in nu/nu mice scarified with VACV strain Lister,
a vaccinal strain, offered a complete protection from disease
development and death, although viral loads in vital organs were
not reported [55]. Comparable conclusions could be drawn with
the HPMPDAP-cream, 100% protection was given against disease
appearance and propagation, while systemic spread of CMLV to
vital organs was delayed but not stopped.
In conclusion, we developed murine models of CMLV
infection, and defined the immunologic parameters induced by
CMLV which represent the basis needed for the further study of
CMLV pathogenesis and for antiviral drug testing. Moreover,
CMLV strains of different pathogenicity might exist [21] and these
models could serve for the evaluation of their virulence. Our
findings demonstrate also that these models could serve for a better
understanding of the immune evasion mechanisms of CMLV,
which were until now hampered by the absence of in vivo models.
The immune modulation offered by CMLV was often character-
ized by cloning a CMLV gene of interest into a VACV backbone
genome [73,74]. We provide here novel tools for avoiding genetic
manipulations between two OPV species, VACV, which can be
pathogenic for humans, and CMLV, which induces a localized to
generalized and lethal disease in camels.
Materials and Methods
Cells and virus
CMLV strain Iran (CML1, kindly provided by H. Meyer,
Bundeswehr Institute of Microbiology, Germany) was used in
these studies [40]. Human embryonic lung (HEL) fibroblast cells
were grown in Earle’s minimum essential medium (MEM Earle’s,
Invitrogen
TM, Merelbeke, Belgium) containing 5% fetal calf serum
(FCS), 0.2% serum substitute for animal cell culture (Ultroser
HG,
PALL Life Sciences, Cergy-Saint-Christophe, France), 1%
HEPES, 1% non-essential amino acids, 1% sodium pyruvate,
and 1% penicillin/streptomycin/glutamine (Invitrogen
TM)a t
37uC under a 5% CO2 atmosphere. Virus was grown and titrated
on HEL cell monolayers. CML1 was purified through a 36%
sucrose cushion. Briefly, HEL cells were infected at a multiplicity
of infection (MOI) of 0.01 for 2 hr in MEM 2% FCS, and then
replaced in fresh MEM 2%. At day 2 post-infection, the
supernatant was removed, cells were scraped in phosphate buffer
saline (PBS) and frozen at 280uC. Infected cells were homoge-
nized on ice in a glass dounce homogenizer (type A pestel) with 15
strokes. Cell debris were removed by centrifugation at 1200 rpm,
4uC, and the supernatant was layered on a cold 36% sucrose
cushion. Following ultracentrifugation (13,500 rpm, 90 min, 4uC),
the viral pellet was resuspended in 1 mM Tris-HCl pH 9.5 and
crude virus stocks were stored at 280uC.
Mice
Female athymic nude (nu/nu) NMRI mice were purchased from
Elevage-Janvier (Le-Genest-St-Isle, France). All experimental and
animal experimentations were completed at biosafety level 2.
Animals were 13 to 15 g (4 to 5 week-old) the day of infection, and
groups were defined as uninfected, CML1-infected, HPMPC-
treated or HPMPDAP-treated. Depending on the experiment, 5 to
20 animals per group were used.
Ethics Statement
All animal work was approved by the Katholieke Universiteit
Leuven Ethics Committee for Animal Care and Use (Permit
number: P044-2010). All animal guidelines and policies were in
accordance with the Belgian Royal Decree of 14 November 1993
concerning the protection of laboratory animals and the European
Directive 86-609-EEC for the protection of vertebrate animals
used for experimental and other scientific purposes. Infections
were performed under anesthesia using ketamine/xylazine in
saline and, when required, euthanasia was done by administration
of pentobarbital sodium.
Animal infections
For i.n. infections, mice were anesthetized using a cocktail of
ketamine/xylazine in saline, and inoculated with 10 ml of PBS
containing 2.0610
6 PFU CML1 (5 ml per nostril) or mock-
inoculated with 10 ml of PBS. For i.c. infections, mice received a
light anesthesia (ketamine/xylazine in saline) and were immobi-
lized manually by one person. Scarifications were made, as
described elsewhere [55], by applying a 10 ml drop of
2.0610
6 PFU CML1 at the lumbosacral region.
Animal’s monitoring and scoring
In all experiments, mice were monitored for body weights,
morbidity and mortality for 45 (i.n. model) or 75 days (i.c. model).
In the i.c. model of infection, the development and propagation of
the lesions were referred to a disease index scored on a 0 to 5 scale
as follow: 0, absence of lesions; 1, appearance of tiny lesions; 2,
visible lesions; 3, enlargement of lesion’s size; 4, increase of lesion’s
severity (bleeding); 5, spreading of the lesions to the tail and/or the
legs. Also, all deaths reported were due to sacrifices based on
humane end-points in order to minimize pain and distress. For the
i.n. model, animals were euthanized because of (i) failure in
gaining weight as compared with uninfected controls (i.e., there
was more than 35% difference in body weight when compared to
uninfected controls) and (ii) severe sickness associated with
development of lesions and/or edemas. Animals responding to
these criteria were also prostrated. In the i.c. model, animals were
euthanized based on severe disease development (high average
disease index) with or without differences in body weight when
compared to uninfected controls; animals met these criteria
around day 75 post-infection.
Antiviral compounds and treatments
(S)-HPMPC was provided by Gilead Sciences (Foster City, CA,
US) and (S)-HPMPDAP was synthesized by Marcela Krec ˇmerova ´
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of Sciences of the Czech Republic, Prague. Animals infected via
the i.c. route received cream-based treatments consisting of a 1%
(S)-HPMPC- or (S)-HPMPDAP in cetomacrogol ointment.
Treatments were applied by light finger-massages on the scarified
zone once per day for 5 days, starting the day of scarification. For
systemic administrations, working solutions were prepared in PBS
at a concentration of 4 mg/ml. Each compound was administrat-
ed intraperitoneally at a dose of 50 mg/kg once per day for 3 days
starting the day of infection.
Tissue collection
To determine the extent of viral replication, 4 mice per group
were euthanized at days 25 and 45 post-i.n. infection, and at
days 30 and 75 post-i.c. infection. Heart punction was
performed to collect blood. Serum was isolated following
clotting of the blood at +4uC, centrifugation and supernatant
w a sc o l l e c t e da n ds t o r e da t220uC. Swabs of the skin of the
lumbosacral region (i.c.), of the tail (i.c. and i.n.), and of the legs
(i.n.) were collected in 500 ml PBS containing 2% FCS (PBS 2%)
a n ds t o r e da t220uC. Lymph nodes, spleen, liver, lungs, back
skin, tail and leg were dissected aseptically. Lymph nodes and
spleen were processed separately, and the isolated cells were
used for flow cytometry and viral DNA quantification. Liver,
lungs and back skin were collected in PBS 2%, weighed, frozen
at 220uC, and homogenized prior DNA extraction. All DNA
extractions were performed by using QIAamp
H DNA Mini and
blood Mini kits (Qiagen, Venlo, Netherlands) following
manufacturer’s instructions, and samples were then subjected
to quantitative real-time PCR (qPCR).
Seroneutralization
Plaque neutralization assays were performed in 96-well
microplates. Each serum was tested individually. Sera were diluted
1 10 in MEM 2%, inactivated for 30 min at 56uC and two-fold
dilutions were done to reach 1 640. CML1, diluted in MEM 2%
to a concentration of 100 TCID50 in 100 ml, was added to each
well containing the sera to test and to the virus-control wells. The
microplates were incubated for 2 h at 37uC. HEL cells,
resuspended in MEM 2%, were then added at a concentration
of 2.8610
4 cells per 80 ml per well. Microplates were incubated for
3 days at 37uC and examined for plaque formation. The
neutralization titer was calculated using the Spearman-Karber
formula which is the negative logarithm of the highest dilution of
serum that caused a 50% reduction in the number of wells
exhibiting CPE. The assays included virus control, cell control,
negative controls of uninfected animals and controls to evaluate
potential toxicity of the serum alone.
Viral DNA detection
qPCR targeting the CMP48L gene (homolog of the F13L gene
of VACV strain Copenhagen) was used to quantify viral DNA.
qPCR was done on 5 ml of total DNA extracted in a 20 ml reaction
volume using the TaqMan
H Fast Universal PCR master mix,
forward primer [59-CAA CTC CAT TAT AGA AGC CAT T-
39], reverse primer [59-CGT VGT TCT TAT CCC AAT TAC
CA-39], and an MGB probe [6-FAM-ATA GAG GAG TTA
AGA TCA GAC TT-MGB] (Applied Biosystems, Halle, Belgium
and Warrington, UK). Reactions were processed by using the
SDS7500Fast apparatus. Plasmid DNA containing the CMP48L
gene was used to obtain the standard curve and to determine the
DNA copy numbers per sample. The limit of detection per 5 ml
sample was 10 DNA copies.
Histopathology
One mouse of each group, i.e., group uninfected or group
CML1, was euthanized and various tissue samples, such as skin,
tail, leg, lungs, lymph nodes, were collected for histological
examinations. Samples were fixed for one day in formol 6% and
then placed in PBS. Samples were embedded in paraffin and 5
micrometer sections were stained with hematoxylin-eosin.
Preparation of cell suspensions
Spleen and pool of draining lymph nodes (DLNs; inguinal,
axillary, mesenteric and lumbar lymph nodes) were isolated from 4
individual mice in each group and processed separately. Organs
were disrupted in cold PBS 2%, and filtered through a 70 mm
nylon cell strainer. For all procedures, cell suspensions were kept
on ice and washings were done with cold PBS 2%. Cell
suspensions from the spleen were washed once, treated with
ammonium chloride and washed again. Lymph node cells were
only washed once. Cells were then counted before antibody (Ab)
staining.
Flow cytometry
The following conjugated Abs, purchased from eBioscience (San
Diego, CA, USA), were used: anti-CD19-FITC (clone 1D3), anti-
Ly-6G (Gr1)-FITC (clone RB6-8C5), anti-CD11c-FITC (clone
N418), anti-CD45R (B220)-PE (clone RA3-6B2), anti-F4/80-PE
(clone BM8), anti-CD11b-APC (clone M1/70), anti-pan-NK cells
(CD49b)-APC (clone DX5). Cell suspensions obtained from the
spleen and lymph nodes (10
6 cells/tube) were blocked with a 1/3
dilution of FcR Blocking Reagent (Miltenyi Biotec, Bergisch
Gladbach, Germany) for 20 min at 4uC, and then stained in PBS
2% for 20 min at 4uC with the Ab of interest. Cells were washed
once with cold PBS 2% between each Ab staining, and washed
twice before fixation with a 3% formaldehyde solution. Fluores-
cence was acquired on a total of 2610
4 cells (spleen) or 1.5610
4
cells (lymph nodes) with a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA, USA) and the data were analyzed with
the Cellquest software (BD Biosciences).
Cytokine assays
The sera of each group of mice were used for cytokine
detection. IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IL-
18, GM-CSF, IFN-c, TNF-a, M-CSF were measured using the kit
Bio-Plex Pro
TM Mouse cytokine multiplex Assay (Biorad,
Nazareth Eke, Belgium), according to manufacturer’s instructions.
IL-6 immunoassays were performed using the kit QuantitineH
(R&D Systems, Minneapolis, US), according to manufacturer’s
instructions. Only cytokine levels over 10 pg/ml were considered
for statistical analyses.
Statistical analyses
All statistical analyses were done with GraphPad Prism 5
software (GraphPad Software Inc., La Jolla, CA, USA). Viral loads
and FACS results were analyzed with Mann Whitney test and
unpaired Student t test, respectively, and survival curves with Log-
rank (Mantel-Cox) test. Statistic significance was defined as follow:
p,0.001 or ***, extremely significant; p,0.01 or **, very
significant; p,0.05 or *, significant; and p.0.05 or ns, not
significant.
Acknowledgments
We would like to thank Steven Carmans, Lies Van den Heurck, Anita
Camps, Kathleen Van Landeghem for excellent technical assistance, and
Lieve Ophalvens for the histology sample preparation.
Pathogenicity of Camelpox Virus in Athymic Mice
PLoS ONE | www.plosone.org 14 June 2011 | Volume 6 | Issue 6 | e21561Author Contributions
Conceived and designed the experiments: SD GA RS. Performed the
experiments: SD TDS TM. Analyzed the data: SD GA RS JJVDO PM.
Contributed reagents/materials/analysis tools: GA RS JJVDO PM. Wrote
the paper: SD. Reviewed and approved the final version to be published:
SD GA RS PM JJVDO TDS TM.
References
1. Afonso CL, Tulman ER, Lu Z, Zsak L, Sandybaev NT, et al. (2002) The
genome of camelpox virus. Virology 295: 1–9.
2. Gubser C, Smith GL (2002) The sequence of camelpox virus shows it is most
closely related to variola virus, the cause of smallpox. J Gen Virol 83: 855–872.
3. Wernery U, Zachariah R (1999) Experimental camelpox infection in vaccinated
and unvaccinated dromedaries. Zentralbl Veterinarmed B 46: 131–135.
4. Al Zi’abi O, Nishikawa H, Meyer H (2007) The first outbreak of camelpox in
Syria. J Vet Med Sci 69: 541–543.
5. Wernery U, Kaaden OR (2002) Infectious diseases in camelids. In: Blackwell
(2nd, rev and enl. ed.). pp 176–187.
6. Davies FG, Mungai JN, Shaw T (1975) Characteristics of a Kenyan camelpox
virus. J Hyg (Lond) 75: 381–385.
7. Jezek Z, Kriz B, Rothbauer V (1983) Camelpox and its risk to the human
population. J Hyg Epidemiol Microbiol Immunol 27: 29–42.
8. Kriz B (1982) A study of camelpox in Somalia. J Comp Pathol 92: 1–8.
9. Bera BC, Shanmugasundaram K, Barua S, Venkatesan G, Virmani N, et al.
(2011) Zoonotic cases of camelpox infection in India. Vet Microbiol In press.
10. von Bomhard W, Mauldin EA, Breuer W, Pfleghaar S, Nitsche A (2010)
Localized cowpox infection in a 5-month-old Rottweiler. Vet Dermatol 22:
111–114.
11. Ninove L, Domart Y, Vervel C, Voinot C, Salez N, et al. (2009) Cowpox virus
transmission from pet rats to humans, France. Emerg Infect Dis 15: 781–784.
12. Kurth A, Straube M, Kuczka A, Dunsche AJ, Meyer H, et al. (2009) Cowpox
virus outbreak in banded mongooses (Mungos mungo) and jaguarundis
(Herpailurus yagouaroundi) with a time-delayed infection to humans. PLoS
One 4: e6883.
13. Campe H, Zimmermann P, Glos K, Bayer M, Bergemann H, et al. (2009)
Cowpox virus transmission from pet rats to humans, Germany. Emerg Infect Dis
15: 777–780.
14. Glatz M, Richter S, Ginter-Hanselmayer G, Aberer W, Mullegger RR (2010)
Human cowpox in a veterinary student. Lancet Infect Dis 10: 288.
15. Bhanuprakash V, Venkatesan G, Balamurugan V, Hosamani M,
Yogisharadhya R, et al. (2009) Zoonotic Infections of Buffalopox in India.
Zoonoses Public Health 57(7-8): e149–155.
16. Abrahao JS, Silva-Fernandes AT, Lima LS, Campos RK, Guedes MI, et al.
(2010) Vaccinia virus infection in monkeys, Brazilian Amazon. Emerg Infect Dis
16: 976–979.
17. Silva DC, Moreira-Silva EA, Gomes JA, Fonseca FG, Correa-Oliveira R (2010)
Clinical signs, diagnosis, and case reports of Vaccinia virus infections.
Braz J Infect Dis 14: 129–134.
18. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK,
et al. (2010) Major increase in human monkeypox incidence 30 years after
smallpox vaccination campaigns cease in the Democratic Republic of Congo.
Proc Natl Acad Sci U S A 107: 16262–16267.
19. Abu Elzein EM, Gameel AA, Ramadan RO, Housawi FM (1999) An eruptive
moderate form of camelpox infection in dromedary camels (Camelus
dromedarius) in Saudi Arabia. Rev Sci Tech 18: 749–752.
20. Kinne J, Cooper JE, Wernery U (1998) Pathological studies on camelpox lesions
of the respiratory system in the United Arab Emirates (UAE). J Comp Pathol
118: 257–266.
21. Otterbein CK, Meyer H, Renner-Muller IC, Munz E (1996) In vivo and in vitro
characterization of two camelpoxvirus isolates with decreased virulence. Rev
Elev Med Vet Pays Trop 49: 114–120.
22. Bhanuprakash V, Balamurugan V, Hosamani M, Venkatesan G, Chauhan B,
et al. (2010) Isolation and characterization of Indian isolates of camel pox virus.
Trop Anim Health Prod 42: 1271–1275.
23. Hafez SM, al Sukayran A, dela CD, Mazloum KS, al Bokmy AM, et al. (1992)
Development of a live cell culture camelpox vaccine. Vaccine 10: 533–539.
24. Pfeffer M, Meyer H, Wernery U, Kaaden OR (1996) Comparison of camelpox
viruses isolated in Dubai. Vet Microbiol 49: 135–146.
25. Duraffour S, Snoeck R, de Vos R, van Den Oord JJ, Crance JM, et al. (2007)
Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox
and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir
Ther 12: 1205–1216.
26. Duraffour S, Vigne S, Vermeire K, Garcel A, Vanstreels E, et al. (2008) Specific
targeting of the F13L protein by ST-246 affects orthopoxvirus production
differently. Antivir Ther 13: 977–990.
27. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, et al. (2005) An orally
bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus
formation and protects mice from lethal orthopoxvirus Challenge. J Virol 79:
13139–13149.
28. Duraffour S, Snoeck R, Krecmerova M, Van den OJ, de Vos R, et al. (2007)
Activities of several classes of acyclic nucleoside phosphonates against camelpox
virus replication in different cell culture models. Antimicrob Agents Chemother
51: 4410–4419.
29. Duraffour S, Andrei G, Snoeck R (2010) Tecovirimat, a p37 envelope protein
inhibitor for the treatment of smallpox infection. IDrugs 13: 181–191.
30. Hostetler KY (2009) Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates
enhance oral antiviral activity and reduce toxicity: current state of the art.
Antiviral Res 82: A84–A98.
31. Centers for Disease Control and Prevention (CDC) (2007) Household
transmission of vaccinia virus from contact with a military smallpox vaccinee--
Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 56: 478–481.
32. Centers for Disease Control and Prevention (CDC) (2009) Progressive vaccinia
in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal
Wkly Rep 58: 532–536.
33. Centers for Disease Control and Prevention (CDC) (2009) Human vaccinia
infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009.
MMWR Morb Mortal Wkly Rep 58: 1204–1207.
34. Bristol N (2007) Adverse event related to smallpox vaccination. Disaster Med
Public Health Prep 1: 11–12.
35. Kaiser J (2007) Smallpox vaccine. A tame virus runs amok. Science 316:
1418–1419.
36. Marris E (2007) Dramatic rescue relieves rare case of smallpox infection. Nat
Med 13: 517.
37. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, et al. (2008) Severe
eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect
Dis 46: 1555–1561.
38. Baxby D (1972) Smallpox-like viruses from camels in Iran. Lancet 2: 1063–1065.
39. Falluji MM, Tantawi HH, Shony MO (1979) Isolation, identification and
characterization of camelpox virus in Iraq. J Hyg (Lond) 83: 267–272.
40. Ramyar H, Hessami M (1972) Isolation, cultivation and characterization of
camel pox virus. Zentralbl Veterinarmed B 19: 182–189.
41. Sehgal CL, Ray SN (1980) Studies on camelpox virus. J Commun Dis 12:
177–182.
42. Tantawi HH, El Dahaby H, Fahmy LS (1978) Comparative studies on poxvirus
strains isolated from camels. Acta Virol 22: 451–457.
43. Tscharke DC, Reading PC, Smith GL (2002) Dermal infection with vaccinia
virus reveals roles for virus proteins not seen using other inoculation routes. J Gen
Virol 83: 1977–1986.
44. Osorio JE, Iams KP, Meteyer CU, Rocke TE (2009) Comparison of monkeypox
viruses pathogenesis in mice by in vivo imaging. PLoS One 4: e6592.
45. Stabenow J, Buller RM, Schriewer J, West C, Sagartz JE, et al. (2010) A mouse
model of lethal infection for evaluating prophylactics and therapeutics against
Monkeypox virus. J Virol 84: 3909–3920.
46. Americo JL, Moss B, Earl PL (2010) Identification of wild-derived inbred mouse
strains highly susceptible to monkeypox virus infection for use as small animal
models. J Virol 84: 8172–8180.
47. Damon I (2007) Poxviruses. In: Knipe DM, Howley PM, eds. Fields Virology
Lippincot Williams & Wilkins. pp 2947–2975.
48. Chapman JL, Nichols DK, Martinez MJ, Raymond JW (2010) Animal models of
orthopoxvirus infection. Vet Pathol 47: 852–870.
49. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, et al. (1997)
Cytokines and immunity to viral infections. Immunol Rev 159: 119–135.
50. Smee DF, Gowen BB, Wandersee MK, Wong MH, Skirpstunas RT, et al.
(2008) Differential pathogenesis of cowpox virus intranasal infections in mice
induced by low and high inoculum volumes and effects of cidofovir treatment.
Int J Antimicrob Agents 31: 352–359.
51. Liu G, Zhai QZ, Schaffner DJ, Wu AG, Yohannes A, et al. (2004) Prevention of
lethal respiratory vaccinia infections in mice with interferon-alpha and
interferon-gamma. Fems Immunology and Medical Microbiology 40: 201–206.
52. Quenelle DC, Collins DJ, Kern ER (2004) Cutaneous infections of mice with
vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res 63: 33–40.
53. Smee DF, Bailey KW, Wong MH, Wandersee MK, Sidwell RW (2004) Topical
cidofovir is more effective than is parenteral therapy for treatment of progressive
vaccinia in immunocompromised mice. Journal of Infectious Diseases 190:
1132–1139.
54. Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, et al. (2010)
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice.
Proc Natl Acad Sci U S A 107: 838–843.
55. Neyts J, Leyssen P, Verbeken E, De Clercq E (2004) Efficacy of cidofovir in a
murine model of disseminated progressive vaccinia. Antimicrob Agents
Chemother 48: 2267–2273.
56. Thin G (1882) The Histology of Molluscum Contagiosum. J Anat Physiol 16:
202–207.
57. Bayer-Garner IB (2005) Monkeypox virus: histologic, immunohistochemical and
electron-microscopic findings. J Cutan Pathol 32: 28–34.
58. Schoepp RJ, Morin MD, Martinez MJ, Kulesh DA, Hensley L, et al. (2004)
Detection and identification of Variola virus in fixed human tissue after
prolonged archival storage. Lab Invest 84: 41–48.
Pathogenicity of Camelpox Virus in Athymic Mice
PLoS ONE | www.plosone.org 15 June 2011 | Volume 6 | Issue 6 | e2156159. Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J (1996) Different
roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control
of a generalized virus infection. J Virol 70: 8301–8309.
60. Chaudhri G, Panchanathan V, Buller RM, van den Eertwegh AJ, Claassen E,
et al. (2004) Polarized type 1 cytokine response and cell-mediated immunity
determine genetic resistance to mousepox. Proc Natl Acad Sci U S A 101:
9057–9062.
61. Buller RM, Palumbo GJ (1991) Poxvirus pathogenesis. Microbiol Rev 55:
80–122.
62. Reading PC, Smith GL (2003) A kinetic analysis of immune mediators in the
lungs of mice infected with vaccinia virus and comparison with intradermal
infection. J Gen Virol 84: 1973–1983.
63. O’Gorman WE, Sampath P, Simonds EF, Sikorski R, O’Malley M, et al. (2010)
Alternate mechanisms of initial pattern recognition drive differential immune
responses to related poxviruses. Cell Host Microbe 8: 174–185.
64. Abadie V, Bonduelle O, Duffy D, Parizot C, Verrier B, et al. (2009) Original
encounter with antigen determines antigen-presenting cell imprinting of the
quality of the immune response in mice. PLoS One 4: e8159.
65. Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, et al. (2006) Poxvirus
CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80:
6318–6323.
66. Knorr CW, Allen SD, Torres AR, Smee DF (2006) Effects of cidofovir treatment
on cytokine induction in murine models of cowpox and vaccinia virus infection.
Antiviral Res 72: 125–133.
67. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a
unique cytokine that stimulates both Th1 and Th2 responses depending on its
cytokine milieu. Cytokine Growth Factor Rev 12: 53–72.
68. Reading PC, Smith GL (2003) Vaccinia virus interleukin-18-binding protein
promotes virulence by reducing gamma interferon production and natural killer
and T-cell activity. J Virol 77: 9960–9968.
69. Alcami A, Smith GL (1995) Vaccinia, cowpox, and camelpox viruses encode
soluble gamma interferon receptors with novel broad species specificity. J Virol
69: 4633–4639.
70. Najarro P, Traktman P, Lewis JA (2001) Vaccinia virus blocks gamma interferon
signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 75:
3185–3196.
71. Smee DF (2008) Progress in the discovery of compounds inhibiting
orthopoxviruses in animal models. Antivir Chem Chemother 19: 115–124.
72. Gammon DB, Snoeck R, Fiten P, Krecmerova M, Holy A, et al. (2008)
Mechanism of antiviral drug resistance of vaccinia virus: identification of
residues in the viral DNA polymerase conferring differential resistance to
antipoxvirus drugs. J Virol 82: 12520–12534.
73. Gubser C, Bergamaschi D, Hollinshead M, Lu X, van Kuppeveld FJ, et al.
(2007) A new inhibitor of apoptosis from vaccinia virus and eukaryotes. PLoS
Pathog 3: e17.
74. Gubser C, Goodbody R, Ecker A, Brady G, O’Neill LA, et al. (2007) Camelpox
virus encodes a schlafen-like protein that affects orthopoxvirus virulence. J Gen
Virol 88: 1667–1676.
Pathogenicity of Camelpox Virus in Athymic Mice
PLoS ONE | www.plosone.org 16 June 2011 | Volume 6 | Issue 6 | e21561